沙特专家关于推进多发性骨髓瘤治疗的声明：双特异性抗体作用的演变

A group of experts in MM based in Saudi Arabia convened to align on optimal use of BsAbs in clinical practice based on their experience and evidence from a literature analysis. A modified Delphi methodology with prespecified acceptance threshold of 70% was used to generate expert recommendations.

Agreement was achieved in 30 of 35 statements (86%) across four broad areas: patient selection, sequencing and dosing, monitoring, and efficacy outcomes. Experts agreed that BsAbs should be positioned in triple-class refractory MM. Positive clinical trial outcomes observed with BsAbs, including high overall response rates, prolonged progression-free survival and overall survival underscore the importance of selecting BsAbs with proven efficacy. While CAR T-cell therapy is only recently approved for MM in Saudi Arabia, BsAbs are preferred for patients with rapidly progressing disease due to CAR T-cell product manufacturing delays.

BsAbs are an effective treatment option for those with triple-class refractory MM and this manuscript provides a framework to support their optimal use in Saudi Arabia.